One of the hypothetical mechanisms in paper revolves around the p53/NFKB axis. The paper cites references that p53 increases mitochondrial energy production and glutathione levels. The inflammatory NFKB suppresses this mechanism and so will increase glycolysis over mitochondrial energy production. Cells and tissues with high NFKB will have lower p53, and this in turn with induce lower Foxp3 (a transcription factor, meaning it can regulate genetic transcription of important RNA in a T cell), which is needed for proper regulatory T cell immune suppression mechanisms.
http://www.ebioscience.com/knowledge-center/antigen/foxp3.htm
An implication of this is that prolonged and intense NFKB expression can drive a loss of immune tolerance. This probably would assist the development of autoantibodies and other autoimmune related mechanisms that has been shown in some of Maes' papers.
All of this so far is either implied or stated in the Maes paper.
Given the high lactate in the brain (consistent with elevated glycolysis or suppressed Krebs cycle) this might mean that brain inflammation is much higher than in the rest of the body, again consistent with many ideas about ME.
According to the wikipedia, which is not a very reliable source but easy to access, decreased or dysfunctional Tregs are associated with lupus, and an improvement in Tregs can benefit diseases including diabetes, MS, asthma and inflammatory bowel disease.
http://en.wikipedia.org/wiki/FOXP3
http://www.ugr.es/~inmuno/Novedades/ego/papersCox/day3/foxp3.pdf
"These T cells, identified by their expression of CD4, the
IL-2Rα chain (CD25), and the forkhead family transcription factor Foxp3, are know as regulatory T cells, or Tregs." [my bolding]
One of the older observations in CFS (probably ME) research is an elevation of sIL2r (soluble interleukin-2 receptor). This is a Treg marker. SIL2r used to be considered a generic marker for autoimmune issues though I think the opinion may have shifted on this, I am out of date. Many CFS (probably ME) patients have this marker.
My question is this: is it possible that regulatory T cells are shedding their sIL2r, or that they are dying, as a result of lowered Foxp3 or other mechanisms? It offers the possibility that sIL2r might be a surrogate marker for Treg health?
From Zeigler: "The primary issue that has confounded these studies is that the factors that appear to affect Foxp3 expression also affect the survival and expansion of Tregs."
To counter this view though it is known that sIL2r occurs on a range of cell types, so the source might not be Tregs at all. Alternatively the shedding of sIL2r could be part of the Treg immunsuppression mechanisms (I have not researched this) and so represent an attempt by the Tregs to suppress an autoimmune problem.
In my case when I was tested in the 90s my sIL2r was thousands of times higher than it should be, but only about 25% of the theoretical maximum - theoretical because people whose sIL2r get anything like that high tend to drop dead.
The Zeigler papers also discusses lymphoproliferative disease in connection with loss of Foxp3. Is this a factor predisposing us to leukemia and lymphoma? If so then its a definite drug target, either directly or indirectly by targeting NFKB or p53. My suspicion though is an intervention aimed at modifying all three would be better.
There is a research interest in using Tregs to alter immunity, though I am wary of using retroviral vectors as discussed by Zeigler. In particular, T cells externally modified with Foxp3 can be used therapeutically to reduce contact hypersensitivity. I wonder if this is related to our skin issues or MCS? It would be interesting to find out.
The Zeigler paper is 7 years old. I am looking for better ones.
Bye, Alex